HRP20220103T1 - Derivati bisamida dikarboksilne kiseline, njihova uporaba, na njima temeljen farmaceutski sastav i postupci za proizvodnju derivata bisamida dikarboksilne kiseline - Google Patents

Derivati bisamida dikarboksilne kiseline, njihova uporaba, na njima temeljen farmaceutski sastav i postupci za proizvodnju derivata bisamida dikarboksilne kiseline Download PDF

Info

Publication number
HRP20220103T1
HRP20220103T1 HRP20220103TT HRP20220103T HRP20220103T1 HR P20220103 T1 HRP20220103 T1 HR P20220103T1 HR P20220103T T HRP20220103T T HR P20220103TT HR P20220103 T HRP20220103 T HR P20220103T HR P20220103 T1 HRP20220103 T1 HR P20220103T1
Authority
HR
Croatia
Prior art keywords
disease
image
dicarboxylic acid
use according
compound
Prior art date
Application number
HRP20220103TT
Other languages
English (en)
Inventor
Vladimir Evgenievich Nebolsin
Tatyana Alexandrovna Kromova
Galina Alexandrovna Zheltukhina
Original Assignee
Treamid Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treamid Therapeutics Gmbh filed Critical Treamid Therapeutics Gmbh
Publication of HRP20220103T1 publication Critical patent/HRP20220103T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)

Claims (17)

1. Derivat bisamida dikarboksilne kiseline iz opće formule: [image] pri čemu: R1 je skupina odabrana iz: [image] i [image] i R2 je skupina odabrana iz: -C(O)-(CH2)0-C(O)-, -C(O)-(CH2)1-C(O)-, -C(O)-(CH2)2-C(O)-, -C(O)-(CH2)3-C(O)-, -C(O)-(CH2)4-C(O)-, -C(O)(CH3)-CH2-C(O)-, i -C(O)-CH2-C(CH3)2-CH2-C(O)-, ili skupina odabrana iz [image] , and = i ili njihova farmaceutski prihvatljiva sol, uz uvjet da taj spoj nije spoj pri čemu: R1 je [image] i R2 je -C(O)-(CH2)3-C(O)-; spoj, pri čemu: R1 je [image] i R2 je -C(O)-(CH2)4-C(O)-
2. Postupak za in vitro keliranje iona metala pomoću derivata bisamida dikarboksilne kiseline iz opće formule: [image] pri čemu: R1 je skupina odabrana iz: [image] i [image] i R2 je skupina odabrana iz: -C(O)-(CH2)0-C(O)-, -C(O)-(CH2)1-C(O)-, -C(O)-(CH2)2-C(O)-, -C(O)-(CH2)3-C(O)-, -C(O)-(CH2)4-C(O)-, -C(O)-CH2-CH(CH3)-CH2-C(O)-, i -C(O)-CH2-C(CH3)2-CH2-C(O)-, ili skupina odabrana iz [image] , and = i ili njegova farmaceutski prihvatljiva sol.
3. Postupak sukladno patentnom zahtjev 2 pri čemu derivat bisamida dikarboksilne kiseline može da kelira ione Zn, Cu, Fe, Mg, i Ca.
4. Farmaceutski sastav za uporabu u sprječavanju i/ili liječenju jedne ili više bolesti odabranih od virusne bolesti, kardiovaskularne bolesti, neurodegenerativne bolesti, kancerogene bolesti, dijabetesa i radi dijabetesa nastalih kardiovaskularnih komplikacija, uslijed prekomjerne nastale anemije, kasne kožne porfirije, alkoholizma ili alkoholne ciroze; ili za liječenje trovanja solima prijelaznog metala, ili za liječenje bolesti povezane s metalom ovisnom reakcijom oksidacije slobodnog radikala, ili za liječenje bolesti uzrokovane mikrobnim toksinima; pri čemu navedeni sastav sadrži učinkovitu količinu spoja iz opće formule I: [image] pri čemu R1 je 5-člana nezasićena heterociklička skupina koja sadrži od 1 do 2 heteroatoma odabrana iz N i/ili S, izborno kondenzirana s 6-članom nezasićenom cikličkom skupinom; R2 je -C(O)-R3-C(O)-, pri čemu R3 je -(CH2)n- izborno supstituirana s jednom ili dvije C1-C6alkil skupine ili fenilom; i n je cijeli broj od 0 do 4; ili njihova farmaceutski prihvatljiva sol.
5. Farmaceutski sastav za uporabu sukladno patentnom zahtjevu 4, pri čemu je virusna bolest uzrokovana hepatitisom C, humanim papiloma virusom, HIV, ili onkogenim RNK virusom kao što je virus leukemije, ili pri čemu je kardiovaskularna bolest uzrokovana citostatičkom kardiotoksičnošću citostaticima, taloženjem kolesterola, ili hipertenzijom.
6. Farmaceutski sastav za uporabu sukladno patentnom zahtjevu 4, pri čemu je ta bolest povezana s metalom ovisnom reakcijom oksidacije slobodnog radikala je bolest povezana sa starenjem, kao što je katarakta, bolest mrežice, ili pigmentacija kože; posljedica moždanog udara; ateroskleroza; ili upalne bolesti, kao što je osteoartritis ili reumatoidni artritis.
7. Farmaceutski sastav za uporabu sukladno patentnom zahtjevu 4, pri čemu je ta neurodegenerativna bolest Alzheimerova bolest, Parkinsonova bolest, Wilsonova bolest, Huntingtonova bolest, amiotrofična lateralna skleroza, ili prionska bolest.
8. Farmaceutski sastav za uporabu sukladno patentnom zahtjevu 4, pri čemu ta bolest uzrokovana mikrobnim toksinima je botulizam ili plinska gangrena.
9. Spoj iz formule I: [image] pri čemu R1 je 5-člana nezasićena heterociklička skupina koja sadrži od 1 do 2 heteroatoma odabranih iz N i/ili S, izborno kondenzirana sa 6-članom nezasićenom cikličkom skupinom; R2 je -C(O)-R3-C(O)-, pri čemu R3 je -(CH2)n- izborno supstituirana s jednom ili dvije C1-C6alkil skupine ili fenilom; i n je cijeli broj od 0 do 4; ili njihovom farmaceutski prihvatljivom soli za uporabu u sprječavanju i/ili liječenju bolesti odabrane od virusne bolesti, kardiovaskularne bolesti, neurodegenerativne bolesti, kancerogene bolesti, dijabetesa i dijabetesom nastalih kardiovaskularnih komplikacija, anemijom nastalom prekomjernim željezom, kasne kožne porfirije, alkoholizma ili alkoholne ciroze, trovanja soli prijelaznog metala, bolesti povezanom s metalom ovisnom reakcijom oksidacije slobodnog radikala, bolesti uzrokovane mikrobnim toksinima.
10. Spoj za uporabu sukladno patentnom zahtjevu 9, pri čemu je virusna bolest uzrokovana virusom hepatitisa C, humanim papiloma virusom, virusom HIV, ili onkogenim RNK virusom, kao što je virus leukemije.
11. Spoj za uporabu sukladno patentnom zahtjevu 9, pri čemu je kardiovaskularna bolest uzrokovana citostatskom kardiotoksičnošću, nagomilavanjem kolesterola, ili hipertenzijom.
12. Spoj za uporabu sukladno patentnom zahtjevu 9, pri čemu ta bolest povezana s metala ovisnom reakcijom oksidacije slobodnog radikala je bolest povezana starenjem, kao što je katarakta, bolest mrežnice, ili pigmentacija kože; posljedice moždanog udara; ateroskleroza; ili upalna bolest, kao što je osteoartritis, ili reumatoidni artritis.
13. Spoj za uporabu sukladno patentnom zahtjevu 9, pri čemu je ta neurodegenerativna bolest Alzheimerova bolest, Parkinsonova bolest, Wilsonova bolest, Huntingtonova bolest, amiotrofična lateralna skleroza, ili prionska bolest.
14. Spoj za uporabu sukladno patentnom zahtjevu 9, pri čemu bolest uzrokovana mikrobnim toksinima je botulizam ili plinska gangrena.
15. Postupak proizvodnje derivata bisamida dikarboksilne kiseline iz opće formule I: [image] pri čemu R1 je 5-člana nezasićena heterociklička skupina koja sadrži od 1 do 2 heteroatoma odabrana iz N i/ili S, izborno kondenzirana sa 6-članom nezasićenom cikličkom skupinom; R2 je -C(O)-R3-C(O)-, pri čemu R3 je -(CH2)n- izborno supstituirana s jednom do dvije C1-C6alkil skupine ili fenilom; i n je cijeli broj od 0 do 4; sadrži kondenziranje dikarboskilne kiseline iz opće formule II: R4O-C(O)-R3-C(O)-OR4, pri čemu R3 je -(CH2)n- izborno supstituirana s jednom ili dvije C1-C6alkil skupine ili fenilom; n je cijeli broj od 0 do 4, i R4 je vodik ili C1-C6alkil, s aminom iz opće formule III: NH2-(CH2)2-R1, pri čemu R1 je 5-člana nezasićena heterociklička skupina koja sadrži od 1 do 2 heteroatoma odabrana iz N i/ili S, izborno kondenzirana sa 6-članom nezasićenom cikličkom skupinom uz zagrijavanje, i izborno uz prisutnost otapala, ili u molarnom odnosu 1:2-2,5 u otopini tetrahidrofurana u prisutnosti neke kondenzirajuće tvari.
16. Postupak sukladno patentnom zahtjevu 15, pri čemu se otapalo izabire od dimetil ili dietil etera dikarboksilne kiseline i korak zagrijavanja se provodi na temperaturi od između 150 i 170°C.
17. Postupak sukladno patentnom zahtjevu 15, pri čemu je ta kondenzirajuća tvar karbonildiimidazol.
HRP20220103TT 2013-04-12 2014-04-10 Derivati bisamida dikarboksilne kiseline, njihova uporaba, na njima temeljen farmaceutski sastav i postupci za proizvodnju derivata bisamida dikarboksilne kiseline HRP20220103T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2013116822A RU2665688C2 (ru) 2013-04-12 2013-04-12 Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
EP14782759.6A EP2985284B1 (en) 2013-04-12 2014-04-10 Dicarboxylic acid bisamide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing dicarboxylic acid bisamide derivatives
PCT/RU2014/000265 WO2014168523A1 (ru) 2013-04-12 2014-04-10 Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения

Publications (1)

Publication Number Publication Date
HRP20220103T1 true HRP20220103T1 (hr) 2022-04-29

Family

ID=51689820

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220103TT HRP20220103T1 (hr) 2013-04-12 2014-04-10 Derivati bisamida dikarboksilne kiseline, njihova uporaba, na njima temeljen farmaceutski sastav i postupci za proizvodnju derivata bisamida dikarboksilne kiseline

Country Status (26)

Country Link
US (3) US20160031858A1 (hr)
EP (1) EP2985284B1 (hr)
JP (1) JP6760837B2 (hr)
KR (1) KR102218134B1 (hr)
CN (6) CN105358548A (hr)
AU (1) AU2014251443C1 (hr)
BR (1) BR112015025675B1 (hr)
CA (1) CA2909411C (hr)
CY (1) CY1125062T1 (hr)
DK (1) DK2985284T3 (hr)
EA (6) EA202092453A3 (hr)
ES (1) ES2904568T3 (hr)
HK (1) HK1221223A1 (hr)
HR (1) HRP20220103T1 (hr)
HU (1) HUE057209T2 (hr)
IL (1) IL242029B (hr)
LT (1) LT2985284T (hr)
MX (2) MX2015014213A (hr)
PL (1) PL2985284T3 (hr)
PT (1) PT2985284T (hr)
RS (1) RS62889B1 (hr)
RU (1) RU2665688C2 (hr)
SG (2) SG11201508342RA (hr)
SI (1) SI2985284T1 (hr)
UA (1) UA119748C2 (hr)
WO (1) WO2014168523A1 (hr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015014336A (es) * 2013-04-12 2016-06-07 Obschestvo S Ogranichennoi Otveststvennostiyu Pharmentpr Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
RU2665688C2 (ru) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
RU2647438C2 (ru) * 2015-05-27 2018-03-15 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
RU2665633C1 (ru) * 2017-05-26 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новый ингибитор глутаминилциклаз и его применение
CN110087650B (zh) * 2017-05-26 2024-03-22 瓦伦塔有限责任公司 新的谷氨酰胺酰基环化酶抑制剂及其在治疗多种疾病中的用途
RU2662559C1 (ru) * 2017-10-27 2018-07-26 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новый ингибитор глутаминилциклаз и его применение для лечения заболеваний легких и дыхательных путей
WO2018237163A1 (en) * 2017-06-23 2018-12-27 Roman Manetsch 5-AMINOLEVULINATE SYNTHASE INHIBITORS AND METHODS OF USE
RU2685277C1 (ru) * 2018-05-24 2019-04-17 Общество с ограниченной ответственностью "Фарминтерпрайсез Аллерджи" Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных
RU2679636C1 (ru) * 2018-10-29 2019-02-12 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новый способ получения n,n'-бис[2-(1н-имидазол-4-ил)этил]малонамида
RU2746692C1 (ru) * 2020-04-14 2021-04-19 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний
WO2021049980A1 (ru) * 2019-09-12 2021-03-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Новые составы для лечения и профилактики вирусных заболеваний
RU2745265C2 (ru) * 2019-09-12 2021-03-22 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новые составы 2-(имидазол-4-ил)-этанамида пентандиовой-1,5 кислоты для лечения и профилактики вирусных заболеваний
WO2023177328A1 (en) 2022-03-17 2023-09-21 Treamid Therapeutics Gmbh Bisamide derivative of dicarboxylic acid for use in restoring the external respiratory function after coronavirus infection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6169759A (ja) * 1984-09-14 1986-04-10 Agency Of Ind Science & Technol タンパク質の架橋反応用修飾剤及びそれを用いる方法
JPS6344567A (ja) * 1986-08-08 1988-02-25 Shikoku Chem Corp 新規なイミダゾール系ジアミド化合物、該化合物の合成方法および該化合物を有効成分とするポリエポキシ樹脂硬化剤
IL86131A0 (en) * 1987-04-24 1988-11-15 Boehringer Ingelheim Kg Benzo-and thieno-3,4-dihydropyridine derivatives,their preparation and pharmaceutical compositions containing them
AU2001283740A1 (en) * 2000-08-17 2002-02-25 University Of British Columbia Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
RU2287524C1 (ru) * 2005-03-31 2006-11-20 ООО "Фарминтерпрайсез" Аспартильные производные гистамина, способ их получения, фармацевтическая композиция и их применение в качестве модуляторов активности ферментов антиоксидантной защиты
RU2335495C2 (ru) * 2005-06-15 2008-10-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств
CN1919884A (zh) * 2005-08-26 2007-02-28 建筑技术研究有限公司 基于氧化烯二醇烯基醚和不饱和二羧酸衍生物的共聚物
AU2006315467B2 (en) * 2005-11-14 2013-02-07 Curis, Inc. Bisamide inhibitors of hedgehog signaling
EP1884515A1 (en) * 2006-07-31 2008-02-06 Laboratorios del Dr. Esteve S.A. Substituted indanyl sulfonamide compounds, their preparation and use as medicaments
JP6079148B2 (ja) * 2012-11-07 2017-02-15 Jsr株式会社 液晶配向剤、液晶配向膜及び液晶表示素子
RU2665688C2 (ru) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
JP6169759B1 (ja) * 2016-07-11 2017-07-26 株式会社山寿セラミックス 弾性表面波素子用基板及びその製造方法

Also Published As

Publication number Publication date
CY1125062T1 (el) 2023-06-09
LT2985284T (lt) 2022-01-25
DK2985284T3 (da) 2022-02-07
US20160031858A1 (en) 2016-02-04
AU2014251443B2 (en) 2018-10-04
EA202092453A3 (ru) 2021-06-30
HK1221223A1 (zh) 2017-05-26
RU2665688C2 (ru) 2018-09-04
JP6760837B2 (ja) 2020-09-23
MX2015014213A (es) 2016-06-02
EA202092453A2 (ru) 2021-02-26
EA202092452A3 (ru) 2021-06-30
WO2014168523A4 (ru) 2015-01-08
SG11201508342RA (en) 2015-11-27
BR112015025675A8 (pt) 2023-04-18
SG10202008505VA (en) 2020-10-29
CN105358548A (zh) 2016-02-24
IL242029B (en) 2020-01-30
CN109096199A (zh) 2018-12-28
EP2985284A4 (en) 2016-12-07
EA201992275A3 (ru) 2020-04-30
CA2909411A1 (en) 2014-10-16
PT2985284T (pt) 2022-01-28
WO2014168523A1 (ru) 2014-10-16
EA202190774A3 (ru) 2021-10-29
AU2014251443A1 (en) 2015-11-19
CN109134378B (zh) 2022-09-20
CN109336819A (zh) 2019-02-15
UA119748C2 (uk) 2019-08-12
US20220324843A1 (en) 2022-10-13
BR112015025675A2 (pt) 2017-07-18
BR112015025675B1 (pt) 2024-01-02
EA201501014A1 (ru) 2016-02-29
JP2016516767A (ja) 2016-06-09
US20230203016A1 (en) 2023-06-29
EA039440B1 (ru) 2022-01-27
CN109336819B (zh) 2022-05-10
RU2013116822A (ru) 2014-10-20
CN109096200A (zh) 2018-12-28
PL2985284T3 (pl) 2022-02-28
CA2909411C (en) 2018-05-22
AU2014251443C1 (en) 2019-05-30
EA202190775A1 (ru) 2021-06-24
HUE057209T2 (hu) 2022-04-28
EA036961B1 (ru) 2021-01-20
CN109096199B (zh) 2022-05-10
KR20150142034A (ko) 2015-12-21
RS62889B1 (sr) 2022-03-31
MX2020013371A (es) 2021-03-09
ES2904568T3 (es) 2022-04-05
EA201992275A2 (ru) 2020-01-16
CN109134378A (zh) 2019-01-04
KR102218134B1 (ko) 2021-02-19
SI2985284T1 (sl) 2022-04-29
EP2985284B1 (en) 2021-11-03
EA202190774A2 (ru) 2021-07-30
CN109096198A (zh) 2018-12-28
CN109096198B (zh) 2022-03-08
EP2985284A1 (en) 2016-02-17
EA202092452A2 (ru) 2021-02-26
CN109096200B (zh) 2022-04-08

Similar Documents

Publication Publication Date Title
HRP20220103T1 (hr) Derivati bisamida dikarboksilne kiseline, njihova uporaba, na njima temeljen farmaceutski sastav i postupci za proizvodnju derivata bisamida dikarboksilne kiseline
JP2016516767A5 (hr)
JP4724665B2 (ja) キノリノン化合物を合成する方法
HRP20160641T1 (hr) Fuzionirani triciklički spojevi kao inhibitori raf kinaze
JP6892876B2 (ja) 免疫調節剤としての三環式化合物
CN113429387B (zh) 一种苯并[b]硒吩类STING调控剂、其制备方法及用途
JP6301369B2 (ja) ホモセリンラクトンの誘導体並びにその調製方法及び使用
JP2015509966A5 (hr)
JP5220087B2 (ja) チオクト酸のｌ−カルニチンとの塩基性塩を含む、医薬組成物および健康補助食品
WO2014138460A1 (en) 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors
JP5763664B2 (ja) 有機ジカルボン酸、その塩およびそれらの調製方法
KR20100052230A (ko) 피타바스타틴 중간체의 제조방법 및 이를 이용한 피타바스타틴 헤미 칼슘염의 제조방법
RU2007146394A (ru) Способы получения гетероциклических соединений
JP5648693B2 (ja) サンショール類の製造方法
FI77848C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva pyrrolidinoner.
AU2007295510A1 (en) Novel phenylacetic acid derivative
WO2011107870A2 (en) Compounds and compositions and their use in the treatment of diseases related to copper retention
RU2018128595A (ru) Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
JP2013506633A (ja) ヒドロキシル化コントラスト増強剤及びその中間体
HRP20070518T5 (hr) DERIVATI 4-OKSO-4,6,7,8-TETRAHIDROPIROLO-1,2-a PIRAZIN-6-KARBOKSAMIDA, POSTUPAK NJIHOVE PRIPRAVE I NJIHOVE FARMACEUTSKE SMJESE
RU2018128627A (ru) Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
RU2018128610A (ru) Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
KR20230024500A (ko) 항바이러스 활성의 화합물 및 이를 포함하는 항바이러스 조성물
RU2018128641A (ru) Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения
JP2535419B2 (ja) スルフィドケトン誘導体およびその製造法